Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 8/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 8/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30217500 | 1.00 | LTB4R (0.40) | LTB4RLTB4R2CYP11B1CYP11B2ADRA2A | |
| SCHEMBL30275375 | 0.92 | PTGDR2 (0.40) | LTB4RLTB4R2CYP11B1CYP11B2ADRA2A | |
| SCHEMBL23980920 | 0.92 | PTGDR2 (0.40) | LTB4RLTB4R2CYP11B1CYP11B2ADRA2A | |
| SCHEMBL23980854 | 0.89 | LTB4R (0.39) | LTB4RLTB4R2CYP11B1CYP11B2ADRA2A | |
| SCHEMBL28949266 | 0.83 | ADRA2A (0.52) | LTB4RLTB4R2CYP11B1CYP11B2ADRA2A | |
| SCHEMBL30217488 | 0.83 | ADRA2A (0.52) | LTB4RLTB4R2CYP11B1CYP11B2ADRA2A | |
| SCHEMBL23980763 | 0.77 | TP53 (0.35) | LTB4RLTB4R2CYP11B1CYP11B2 | |
| SCHEMBL28949267 | 0.76 | ADRA2A (0.40) | CYP11B1CYP11B2ADRA2AADRA2BADRA2C | |
| SCHEMBL23980810 | 0.76 | GLP1R (0.43) | LTB4RLTB4R2CYP11B1CYP11B2ADRA2A | |
| SCHEMBL31707542 | 0.73 | TP53 (0.34) | LTB4RLTB4R2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4143183-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| CN-115667250-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | LTB4R 1089/4885LTB4R2 1206/4885CYP11B1 970/4885 |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GLP1R, NPY1R, NPY2R | LTB4R 1427/4885LTB4R2 1284/4885CYP11B1 474/4885 |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | LTB4R 1089/4885LTB4R2 1206/4885CYP11B1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.